Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50)”
From Hypoglycemia (2018) · cites this paper as [48]
In the citing paper
“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [127]
In the citing paper
“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“In addition, regulatory hurdles from the US FDA, despite pivotal trials done by the Collaborative Islet Transplant group, 62 have been a major stumbling block for the development of islet transplantation technology in the USA.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“5,000 islet equivalents (IEQ)/kg for the first dose and $4,000 IEQ/kg for subsequent doses (if any), was prepared from a single pancreas (14) and was transplanted by portal vein infusion.”
MethodResultSelf-citationStandards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651 · cited 1×
“Recipient Selection Inclusion criteria included the following: age 18–65 years; T1D for $5 years; absent stimulated C-peptide; IAH and/ or marked glycemic lability (19,20); and a history of SHEs in the prior 12 months despite medical care provided by an endocrinologist or diabetologist, who asserted that the candidate…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Items 401–500 of 705
Danobeitia, J. S., Chlebeck, P. J., Shokolenko, I. N., Ma, X., Wilson, G. L., & Fernandez, L. A. (2017) · Cell Transplantation · doi:10.1177/0963689717727542 · Cited by 7
“hypoglycemic events, and normalization of glycemic control in approximately 88% of participants.(42) However, the widespread success of islet transplantation has been limited by the need for multiple donor pancreata and repeated islet infusions to achieve insulin independence in recipients.”
BackgroundDunn, A., Lam, A. P., Hidalgo, L. G., Shapiro, A. M. J., & Senior, P. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01652 · Cited by 7
Self-citationLong-term Persistence of Allosensitization After Islet Allograft Failure
Ríos, P., Baidal, D. A., Lemos, J. R. N., Camhi, S. S., Infante, M., Padilla, N., Gil, A. M. A., Fuenmayor, V., Ambut, J., Qasmi, F. A., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003635 · Cited by 7
“In the group of subjects with graft function, 50% underwent induction with T-cell depleting agents (alemtuzumab or antithymocyte globulin).(1,18,19)”
MethodSelf-citationCurrent Challenges in Pancreas and Islet Transplantation: A Scoping Review
Altabas, V., & Bulum, T. (2024) · Biomedicines · doi:10.3390/biomedicines12122853 · Cited by 6
Current status of pancreatic islet xenotransplantation
Kim, J. M., & Park, C. (2025) · Clinical Transplantation and Research · doi:10.4285/ctr.24.0046 · Cited by 6
Cell Therapy for T1D Beyond BLA: Gearing Up Toward Clinical Practice
Wang, Y., Chen, Y., McGarrigle, J. J., Cook, J., Rios, P., Monica, G. L., Wei, W., & Oberholzer, J. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01732-9 · Cited by 6
“Furthermore, candidates must be free from significant cardiovascular, respiratory, liver, or neurological conditions and should not have any active infections [13, 22].”
Self-citationEmerging role of gene therapy in immune modulation and beta-cell preservation in Type 1 diabetes
Mittal, R., Mutha, V., Valerio, E. A., Hirani, K., Arevalo, G., Panchal, A., Mittal, M., Lemos, J. R. N., & Hirani, K. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2522869 · Cited by 6
Standardized dynamic glucose testing reveals donor-dependent heterogeneity in human islet function
Gnanasekar, P., Saponaro, C., Mühlemann, M., Amassogo, C. A., Coddeville, A., Thévenet, J., Delalleau, N., Petit, P., Hanssen, A., Pasquetti, G., et al. (2025) · Cell Transplantation · doi:10.1177/09636897251350654 · Cited by 6
Modulating immune response for the prevention and treatment of type 1 diabetes
Vohidova, D., Desai, P., Lozano, A. M., & Veiseh, O. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1715863 · Cited by 6
Tada, S., Anazawa, T., Shindo, T., Yamane, K., Inoguchi, K., Fujimoto, N., Nagai, K., Masui, T., Okajima, H., Takaori, K., et al. (2020) · Transplantation Direct · doi:10.1097/txd.0000000000001045 · Cited by 6
Clinical Trials with Stem Cell-Derived Insulin-Producing Cells
Lei, J., & Markmann, J. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_23 · Cited by 6
Self-citationImmunomodulatory agents and cell therapy for patients with type 1 diabetes
Rodacki, M., Silva, K. R., Araújo, D. B., Dantas, J. R., Ramos, M. E. N., Zajdenverg, L., & Baptista, L. S. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0233 · Cited by 6
“Therefore, other cell therapies and alternatives to protect the transplanted cells are under investigation (122-124).”
Metabolic and endocrine evaluation of islet transplant function
Rickels, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00045-9 · Cited by 6
Self-citationIslet Cell Transplantation and Alternative Therapies
Hatipoğlu, B. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.004 · Cited by 6
Local Sphingosine Kinase 1 Activity Improves Islet Transplantation
Rojas‐Canales, D. M., Penko, D., Min, K. K. M., Parham, K. A., Peiris, H. S., Haberberger, R. V., Pitson, S. M., Drogemuller, C., Keating, D. J., Grey, S. T., et al. (2017) · Diabetes · doi:10.2337/db16-0837 · Cited by 6
Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention
Kahkoska, A. R., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0020 · Cited by 6
“2 years (15), although this approach carries additional risks, expenses, and uncertain long-term benefit (16).”
BackgroundYamane, K., Anazawa, T., Tada, S., Fujimoto, N., Inoguchi, K., Emoto, N., Nagai, K., Masui, T., Okajima, H., Takaori, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69009-8 · Cited by 6
Bhagchandani, P., Ramos, S. A., Rodriguez, B., Gu, X., Pathak, S., Zhou, Y., Moon, Y., Nourin, N., Chang, C., Poyser, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci190034 · Cited by 5
“Islet transplantation from cadaveric human donor pancreas is a promising FDA-approved treatment for T1D (2, 3).”
DEC1 regulates human β cell functional maturation and circadian rhythm
Preza, S., Zheng, B., Gao, Z., Biju, A., Liu, M., Cheng, Z., Choi, M., & Alvarez‐Dominguez, J. R. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116666 · Cited by 5
“59 This delay likely reflects a need for SC-islets to complete functional maturation in vivo, in line with gradual molecular changes observed after transplant.”
Establishing a national program of islet transplantation in Australia.
Pj, O., & Kay, T. (2019) · PubMed · doi:10.32113/cellr4_201911_2797 · Cited by 5
Pancreatic Islet Cell Transplantation: Graft Stability and Metabolic Outcomes
Ali, K. F., & Hatipoğlu, B. (2020) · OBM Transplantation · doi:10.21926/obm.transplant.2003115 · Cited by 5
“Finally, recent evidence suggests that the latter liver-related factors might be the confounding factor in the relationship between islet mass yield and metabolic outcomes posttransplantation, thereby mandating more research on extra-hepatic sites of transplant [27].”
BackgroundMichalak, M., Zozulińska‐Ziółkiewicz, D., Michalak, M., Cieluch, A., Michalski, M., & Araszkiewicz, A. (2025) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16945 · Cited by 5
Xenotransplantation of the endocrine pancreas
Smood, B. F., Bottino, R., & Cooper, D. K. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814831-0.00031-2 · Cited by 5
Pasquetti, G., Thévenet, J., Chetboun, M., Apete, A., Gmyr, V., Delalleau, N., Bonner, C., Vantyghem, M., Hübert, T., Pattou, F. N., et al. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00057-5 · Cited by 5
The Roles of Collagen in Islet Transplantation
Sakata, N., Yoshimatsu, G., & Kodama, S. (2020) · OBM Transplantation · doi:10.21926/obm.transplant.2004127 · Cited by 5
“0% or less and prevented severe hypoglycemic events at 1 and 2 years, respectively, after the first transplantation [3].”
Background(2021) · Transplant International · doi:10.1111/tri.13931 · Cited by 5
Lemos, N. E., Dieter, C., Farias, M. G., Rheinheimer, J., de Souza, B. M., Bauer, A. C., & Crispim, D. (2021) · Clinical & Biomedical Research · doi:10.22491/2357-9730.108136 · Cited by 5
Augmenting engraftment of beta cell replacement therapies for T1DM
Aggarwal, S., Pepper, A. R., & Jahdhami, N. A. (2021) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2021.100058 · Cited by 5
Rakotoarisoa, L., Wagner, C., Munch, M., Renaud-Picard, B., Grenet, D., Olland, A., Greget, M., Enescu, I., Bouilloud, F., Bonnette, P., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17058 · Cited by 5
Tun, S. B. B., Chua, M., Tan, G. S. W., Leibiger, I. B., Ali, Y., Barathi, V. A., & Berggren, P. (2022) · Cell Transplantation · doi:10.1177/09636897221098038 · Cited by 5
Walker, S. L. M., Noble, J., Thomson, A. J. W., MORAN, C. M., Mellis, D. J., Lee, I.-N., White, L. J., & Forbes, S. (2023) · Diabetic Medicine · doi:10.1111/dme.15192 · Cited by 5
“This therapy is only used in these select patients due to the requirement of immunosuppression for the lifetime of the graft, 9,10 and because the graft does not normally result in long-term insulin independence but typically restores hypoglycaemic awareness.”
Bond, Z., Malik, S., Bashir, A., Stocker, R., Buckingham, J., Speight, J., & Shaw, J. (2023) · Transplant International · doi:10.3389/ti.2023.11659 · Cited by 5
“Exclusion of all with HbA1c >7% from the “Good” function category has been more contentious, even though HbA1c <7% was agreed by NICE as a key performance indicator for reimbursed islet transplantation and formed part of the primary outcome measure for the US Phase 3 trials towards islet transplant licensing [3, 19].”
BackgroundBuémi, A., Mourad, N. I., Ambroise, J., Hoton, D., Devresse, A., Darius, T., Kanaan, N., Gianello, P., & Mourad, M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1345351 · Cited by 5
“Nonetheless, the scarcity of suitable donor pancreata poses a signi fi cant hurdle to the widespread adoption of this therapeutic approach (3).”
BackgroundSevastianov, V. I., Ponomareva, A. S., Baranova, N. V., Belova, A. D., Kirsanova, L. A., Nikolskaya, A. O., Kuznetsova, E. G., E.O.Chuykova, E. O. C., Skaletskiy, N. N., Skaletskaya, G. N., et al. (2024) · Life · doi:10.3390/life14111505 · Cited by 5
Azad, A., Altunbaş, H., & Manguoğlu, A. E. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347263 · Cited by 5
“Instead, islet transplantation was shown to be safe and effective with less surgical intervention [9,10].”
BackgroundHoldcraft, R. W., Dumpala, P. R., Smith, B. H., & Gazda, L. S. (2018) · Xenotransplantation · doi:10.1111/xen.12443 · Cited by 5
Rickels, M. R., Eggerman, T. L., Bayman, L., Qidwai, J. C., Alejandro, R., Bridges, N. D., Hering, B. J., Markmann, J. F., Senior, P. A., & Hunsicker, L. G. (2022) · doi:10.2337/figshare.21120631 · Cited by 5
Self-citationCavalli, E., Nicoletti, G. R. P., & Nicoletti, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165621 · Cited by 4
“This strategy demonstrated that short-term insulin independence is achievable in patients with severe hypoglycemia or brittle diabetes [98,99], and subsequent registry analyses have confirmed improved outcomes over the past two decades, thereby providing proof-of-concept that functional β -cell…”
Impact of Islet Transplantation on Type 1 Diabetes-Related Complication: A Systematic Review
Gariani, K., Peloso, A., Haidar, F., Kumar, R., Wassmer, C., Morabito, M., Krause, N., Compagnon, P., Berishvili, E., & Berney, T. (2025) · Transplant International · doi:10.3389/ti.2025.15091 · Cited by 4
“This decline appeared to be more pronounced during the fi rst post-transplant year, with reductions in eGFR reaching up to 10 mL/min, followed by stabilization in the subsequent years [26, 28, 35].”
Fisher, M. S., Philippova, J., Васильевич, К. В., & Sennikov, S. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311563 · Cited by 4
“…(Lantidra/donislecel) for adults with severe hypoglycemia unawareness, while stem cell-derived islet replacement therapies (e.g., zimis-lecel, Vertex Pharmaceuticals) are in Phase 3 trials in 2025, achieving insulin independence in ≥ 80% of recipients at 1 year in pivotal studies [12,13].”
Yabe, S. G., Fukuda, S., Nishida, J., Takeda, F., & Okochi, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19972 · Cited by 4
Imaging in Type 1 Diabetes, Current Perspectives and Directions
Tinklepaugh, J., & Mamrak, N. E. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01873-y · Cited by 4
Islet Macroencapsulation: Strategies to Boost Islet Graft Oxygenation
Ludwig, B., Heller, C., Sarangova, V., & Welzel, P. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_12 · Cited by 4
Efthymiadis, A., Bastounis, A., Liu, L. L., Bourlaki, M., Spinos, D., & Tsikopoulos, K. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01492-6 · Cited by 4
Ouahmi, H., Massa, F., Cougnon, M., Rubera, I., Jarretou, G., Tauc, M., OBBERGHEN, E. V., Sicard, A., & Pisani, D. F. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00631.2025 · Cited by 4
Evaluation of collagenase gold plus BP protease in isolating islets from human pancreata
Khiatah, B., Tucker, A., Chen, K.-T., Perez, R. G., Bilbao, S., Valiente, L., Medrano, L. J., Rawson, J., Forouhar, E., Omori, K., et al. (2018) · Islets · doi:10.1080/19382014.2017.1417716 · Cited by 4
“Clinical islet transplantation has been shown to be an effective treatment for patients with brittle type 1 diabetes.(1) The islet yield and quality from pancreas digestion are critically important for achieving this goal.”
BackgroundChinen, K., Sakata, N., Yoshimatsu, G., Nakamura, M., & Kodama, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00740-6 · Cited by 4
Engineering strategies of islet products for endocrine regeneration
Cheng, Y., & Zhao, G. (2023) · Engineered Regeneration · doi:10.1016/j.engreg.2023.01.003 · Cited by 4
Leishman, D. J., Oppler, S. H., Stone, L. H., O’Brien, T. D., Ramachandran, S., Willenberg, B. J., Adams, A. B., Hering, B. J., & Graham, M. L. (2024) · Frontiers in Transplantation · doi:10.3389/frtra.2024.1352777 · Cited by 4
Self-citationToni, T. D., Buono, T. D., Li, C. M., Gonzalez, G. C., Chuang, S.-T., Buchwald, P., Tomei, A. A., & Velluto, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16050652 · Cited by 4
Cautious Optimism Warranted for Stem Cell-Derived Islet Transplantation in Type 2 Diabetes
Scholz, H., Sordi, V., & Piemonti, L. (2024) · Transplant International · doi:10.3389/ti.2024.13358 · Cited by 4
Reformed islets: a long-term primary cell platform for exploring mouse and human islet biology
Haq, N., Toczyska, K., Wilson, M. E., Jacobs, M., Zhao, M., Yu, L., Shen, Z., Pearson, J. A., Persaud, S. J., Pullen, T. J., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02234-6 · Cited by 4
Anazawa, T., Marubashi, S., Kodama, S., Goto, M., Maruyama, M., Eguchi, H., Shimoda, M., Noguchi, H., Yamaguchi, T., Ito, T., et al. (2025) · Transplantation Direct · doi:10.1097/txd.0000000000001765 · Cited by 4
Lundberg, M., Stenwall, A., Tegehall, A., Korsgren, O., & Skog, O. (2018) · Islets · doi:10.1080/19382014.2018.1433980 · Cited by 4
Self-citationKim, J. M., Shin, J., Han, S., Min, B., Jeong, W. Y., Lee, G. E., Kim, M. S., Kwon, S., Chung, H., Kang, H. J., et al. (2018) · Xenotransplantation · doi:10.1111/xen.12460 · Cited by 4
Alcazar, O., Álvarez, A., Ricordi, C., Linetsky, E., & Buchwald, P. (2020) · Cell Transplantation · doi:10.1177/0963689720908278 · Cited by 4
Self-citationThe History of Clinical Islet Transplantation in Japan
Ito, T., Kenmochi, T., Kurihara, K., & Aida, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061645 · Cited by 4
“It was reported that the longterm outcomes of islet transplantation were improved by induction therapy with antithymocyte globulin and anti-TNFα antibody followed by maintenance therapy with lowdose tacrolimus, sirolimus, or mycophenolate mofetil in a multicenter phase III clinical trial [12].”
Pluripotent Stem Cell–Derived Islet Replacement Therapy for Diabetes
Brandon, E. P., Scott, M. J., Zimmerman, M. C., & D’Amour, K. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00006-6 · Cited by 4
Otsuka, R., Miyagi‐Shiohira, C., Kuwae, K., Nishime, K., Tamaki, Y., Yonaha, T., Sakai‐Yonaha, M., Yamasaki, I., Shinzato, M., Saitoh, I., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154290 · Cited by 4
Ye, Z., Zhao, H., & Ye, X. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13698 · Cited by 3
“The treatment of diabetes dates back to 1967, when Paul lacy pioneered islet transplantation in mice, demonstrating the therapeutic potential of cell therapy for diabetes (143). a clinical trial in 2016 also achieved the treatment of T1d through human islet transplantation (144).”
Palummieri, G., Saadat, S., Chuang, S.-T., Buchwald, P., & Velluto, D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101337 · Cited by 3
“Despite significant progress [16], the widespread application of islet transplantation remains limited by two major challenges: the scarcity of donor islets and the need for chronic systemic immunosuppression to prevent graft rejection [17].”
Kawai, K., Doğan, F., Alagpulinsa, D. A., Pop, R., Veres, A., Sobell, D., Deng, H., Collins, S. H., Zhang, J., Chapin, M. H., et al. (2025) · Xenotransplantation · doi:10.1111/xen.70098 · Cited by 3
Self-citationKaraoğlu, İ. C., Odabas, A., Önder, T. T., & Kızılel, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1759835 · Cited by 3
Campa‐Carranza, J. N., Capuani, S., Willman, M. A., Rabassa, A., Joubert, A. L., Bo, T., Franco, L., Conte, M., Anaya‐García, A. L., Rome, G. E., et al. (2026) · Advanced Science · doi:10.1002/advs.202520914 · Cited by 3
Translational Barriers to AAV and CRISPR Gene Therapy in Diabetes
Alharbi, A. G. (2026) · Saudi Medical Journal · doi:10.15537/1658-3175.1061 · Cited by 3
“Future success will likely necessitate gene therapy with traditional treatments, immunomodulatory agents, and regenerative medicine [87].”
Application of Microfluidic Biochips for Human Islet Transplantation
Holzer, J., Wu, J. C.-C., He, Y., Ma, M., Yuan, X., Oberholzer, J., & Wang, Y. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1804034 · Cited by 3
Self-citationCaldara, R., Tomajer, V., & Piemonti, L. (2023) · Transplant International · doi:10.3389/ti.2023.11565 · Cited by 3
Stem Cell-Derived Insulin-Producing β Cells to Treat Diabetes
Harb, G., Poh, Y., & Pagliuca, F. W. (2017) · Current Transplantation Reports · doi:10.1007/s40472-017-0161-x · Cited by 3
Regulation of Inflammatory Response in Islet Transplantation
Shindo, Y., & Kanak, M. A. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1802013 · Cited by 3
Epigenetic biomarkers indicate islet cell death in xenotransplantation
Faulk, C. D., Mueller, K. R., Cheishvili, D., Colwell, M., Pépin, A.-S., Syzf, M., Hering, B. J., & Burlak, C. (2020) · Xenotransplantation · doi:10.1111/xen.12570 · Cited by 3
Self-citationProtective effect of necrostatin-1 on the damage of pancreas islet cells induced by TNF-α.
Ye, B., Rong, P., Liu, L., Wang, W., & Zhang, S. (2020) · PubMed · doi:10.11817/j.issn.1672-7347.2020.190534 · Cited by 3
Yonaha, T., Miyagi‐Shiohira, C., Kuwae, K., Tamaki, Y., Nishime, K., Sakai‐Yonaha, M., Saitoh, I., Watanabe, M., & Noguchi, H. (2020) · Xenotransplantation · doi:10.1111/xen.12661 · Cited by 3
Korbutt, G. S., & Pepper, A. R. (2021) · Transplantation · doi:10.1097/tp.0000000000003746 · Cited by 3
Bertera, S., Knoll, M. F., Knoll, C. A., Hara, H., Kimbrel, E. A., Kouris, N. A., Lanza, R., Philips, B. E., Garciafigueroa, Y., Giannoukakis, N., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.660877 · Cited by 3
Oxygenation and vascularization of pancreatic islet graft: An overview
Cristante, J., Tubbs, E., Benhamou, P., & Lablanche, S. (2021) · Trends in Transplantation · doi:10.15761/tit.1000307 · Cited by 3
“In 2016, a prospective multicentric clinical trial confirmed the efficacy of islet transplantation on metabolic results [19].”
AP39, a Mitochondrial-Targeted H2S Donor, Improves Porcine Islet Survival in Culture
Shinzato, M., Miyagi‐Shiohira, C., Kuwae, K., Nishime, K., Tamaki, Y., Yonaha, T., Sakai‐Yonaha, M., Yamasaki, I., Otsuka, R., Saitoh, I., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185385 · Cited by 3
Alhaidar, M., Soliven, B. C., Liao, C., Rubeiz, H., Ogledzinski, M., Witkowski, P., & Rezania, K. (2023) · Muscle & Nerve · doi:10.1002/mus.27930 · Cited by 3
Stratégie de transplantation chez les patients diabétiques de type 1
Buron, F., Badet, L., & Morélon, E. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.006 · Cited by 3
Loganathan, G., Hughes, M. G., Szot, G. L., Smith, K. E., Hussain, A., Collins, D. R., Green, M. L., Dwulet, F. E., Williams, S. K., Papas, K. K., et al. (2019) · OBM Transplantation · doi:10.21926/obm.transplant.1902064 · Cited by 3
Human embryonic stem cells (hESC) as a source of insulin-producing cells
Sackett, S. D., Tremmel, D. M., Feeney, A. K., Mitchell, S. A., & Odorico, J. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814831-0.00027-0 · Cited by 3
Treating diabetes with islet cell transplantation: Lessons from the Edmonton experience
Dajani, K. Z., & Shapiro, A. M. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00054-x · Cited by 3
Self-citationBaidal, D. A., Infante, M., Fuenmayor, V., Alvarez, A., Padilla, N., Berman, D. M., Pileggi, A., Linetsky, E., Ciancio, G., Ricordi, C., et al. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814831-0.00019-1 · Cited by 3
Self-citationDiabetes Mellitus and iPSC-Based Therapy
Chhetri, D., Amarnath, R. N., Samal, S., Palaniyandi, K., & Gnanasampanthapandian, D. (2023) · Springer eBooks · doi:10.1007/978-981-19-0027-3_10 · Cited by 3
da Silva, C. L. L. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2018.tde-24082018-083447 · Cited by 3
Challenges in stem cell-derived islet replacement therapy can be overcome
Abdulreda, M. H., & Berggren, P.-O. (2021) · Cell Transplantation · doi:10.1177/09636897211045320 · Cited by 2
An unmet need: Pancreatic beta cell replacement
Mohamed, F., Adams, C., & Mansfield, B. S. (2024) · South African Medical Journal · doi:10.7196/samj.2024.v114i3b.1249 · Cited by 2
“[47,48] Furthermore, individuals should be aged >18 years to avoid the risks of chronic immunosuppression in childhood and adolescence.”
BackgroundMethodPhotiadis, S. J., Quynh, N., Montanez, G., Nguyen, C., Kramer, T., Photiadis, D., Sylvia, C., Spangler, T., & Nguyen, K. H. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.11.012 · Cited by 2
Factors determining the prognosis of people with type 1 diabetes – current perspective
Araszkiewicz, A., Trzaska, K., Soukharev, A., Spławski, J., Wolbach, J., Marek, P., Dubel, K., Wojak, W., & Zozulińska‐Ziółkiewicz, D. (2025) · Journal of Medical Science · doi:10.20883/medical.e1122 · Cited by 2
Wu, Q., Yuan, Y., Yang, H., & Fu, Q. (2025) · Transplantation Reviews · doi:10.1016/j.trre.2025.100962 · Cited by 2
A Report of Four Depletional Induction Strategies in Non‐Human Primate Islet Xenotransplantation
Hu, M., Gao, Q., Ladowski, J. M., Anwar, I. J., DeLaura, I. F., Miller, A., Tunbridge, M. J., Song, M., Luo, X., Li, S., et al. (2026) · Xenotransplantation · doi:10.1111/xen.70108 · Cited by 2
Self-citationBühler, B. D., Taeye, S. D., Kinoshita, K., Terashita, M., Maenaka, A., Lavalla, G., Burdorf, L., Bottino, R., & Cooper, D. K. C. (2026) · Diabetes · doi:10.2337/db25-0769 · Cited by 2
Acceptance of encapsulated porcine islet xenotransplantation by patients and doctors in the US
Matsumoto, S., & Yamamoto, N. (2023) · Medicine Advances · doi:10.1002/med4.29 · Cited by 2
Patient Selection: Pancreas or Islet Transplantation
Rao, S., Stumpf, M. M., & Brayman, K. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_18 · Cited by 2
Inagaki, N. F., Oki, Y., Ikeda, S., Tulakarnwong, S., Shinohara, M., Inagaki, F. F., Ohta, S., Kokudo, N., Sakai, Y., & Ito, T. (2024) · Biomaterials Science · doi:10.1039/d4bm00295d · Cited by 2
Odhaib, S. A., Mohammed, A. G., & Iraqi, H. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_192_24 · Cited by 2
Eligibility of patients with type 1 diabetes for islet transplantation alone
Berney, T., Ahmed, M. A., Gastaldi, G., & Andrès, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00033-2 · Cited by 2
Pancreas and islet preservation
Papas, K. K., & León, H. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00042-3 · Cited by 2
Transplantation technologies for treatment of carbohydrate metabolism disorders
Загайнов, В. Е., Meleshina, A. V., Георгиевна, К. К., Васенин, С. А., & Вадимовна, З. Е. (2020) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2020-1-184-195 · Cited by 2
“Лучшие исходы ТОК отме‐ чаются в центрах, максимально точно придержи‐ вающихся стандартов процедуры, установленных в Эдмонтоне [20].”
Akashi, Y., Anazawa, T., Fujikura, J., & Park, C. (2021) · Springer eBooks · doi:10.1007/978-981-16-4597-6_24 · Cited by 2
Effect of Thioketal Antioxidants on Islet Cell Transplantation
Raj, S., Waduthanthri, K. D., Kuppan, P., Korbutt, G. S., Unsworth, L. D., & Pepper, A. R. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200132 · Cited by 2
Metadata
- Authors
- Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., Robien, M. A., Senior, P. A., Shapiro, A. M. J., Stock, P. G., Turgeon, N. A., & for the Clinical Islet Transplantation Consortium
- Affiliations
- University of Minnesota (US)
- University of Iowa (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of Wisconsin–Madison (US)
- Uppsala University (SE)
- Emory University (US)
- Northwestern University (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL
- University of California, San Francisco (US)
- University of Alberta (CA)
- Corresponding author
- Clarke, William R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-18
- Volume
- 39
- Issue
- 7
- Pages
- 1230-1240
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5317236
- OpenAlex
- W2341414956
- Cited by
- 645
- References
- 40
- Citations by year
- 2026: 25 · 2025: 51 · 2024: 47 · 2023: 67 · 2022: 75 · 2021: 88 · 2020: 60 · 2019: 79 · 2018: 73 · 2017: 60 · 2016: 20
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institute for Diabetes and Digestive and Kidney Diseases (U01-AI-089317, 1-AI-089316, 1-AI-065191, U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK-070460, U01-AI-065193, U01-DK-070430, U01-AI-065192)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, islet transplantation, severe hypoglycemia, hypoglycemia unawareness, glycemic control, HbA1c, immunosuppression, bleeding complications, glomerular filtration rate, donor-specific antibodies, renal function decline, islet autoimmunity
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Immunosuppression Therapy, Male, Middle Aged, North America, Islets of Langerhans Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.